Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
United Therapeutics Corporation (UTHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
United Therapeutics Corporation ( UTHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Harrison Silvers - Manager of Investor Relations James Edgemond - CFO & Treasurer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Welcome, everyone, to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts cover SMid-cap biotech in the U.S. It is my pleasure to have the fireside chat with our next company, United Therapeutics, James and Harry.
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript
United Therapeutics Corporation ( UTHR ) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Patrick Poisson - Executive VP of Technical Operations Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Terence Flynn - Morgan Stanley, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. Welcome to UBS Healthcare Conference.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark
UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.
United Therapeutics Corporation (UTHR) Q3 2025 Earnings Call Transcript
United Therapeutics Corporation ( UTHR ) Q3 2025 Earnings Call October 29, 2025 9:00 AM EDT Company Participants Harrison Silvers - Manager of Investor Relations Martine Rothblatt - Founder, Chairman & CEO Michael Benkowitz - President & COO Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation Patrick Poisson - Executive VP of Technical Operations Conference Call Participants Lisa Walter - RBC Capital Markets, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Joseph Thome - TD Cowen, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Jiale Song - Jefferies LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the United Therapeutics Corporation Third Quarter 2025 Corporate Update. My name is Jamie, and I will be your conference operator today.
Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
